Effects of a single-dose methylphenidate challenge on resting-state functional connectivity in stimulant-treatment naive children and adults with ADHD

Antonia Kaiser | Caroline Broeder | Jessica R. Cohen | Linda Douw | Liesbeth Reneman | Anouk Schrantee

1Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands
2Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
3Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Correspondence
Anouk Schrantee, Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
Email: a.g.schrantee@amsterdamumc.nl

Abstract
Prior studies suggest that methylphenidate, the primary pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), alters functional brain connectivity. As the neurotransmitter systems targeted by methylphenidate undergo significant alterations throughout development, the effects of methylphenidate on functional connectivity may also be modulated by age. Therefore, we assessed the effects of a single methylphenidate challenge on brain network connectivity in stimulant-treatment naïve children and adults with ADHD. We obtained resting-state functional MRI from 50 boys (10–12 years of age) and 49 men (23–40 years of age) with ADHD (DSM IV, all subtypes), before and after an oral challenge with 0.5 mg/kg methylphenidate; and from 11 boys and 12 men as typically developing controls. Connectivity strength (CS), eigenvector centrality (EC), and betweenness centrality (BC) were calculated for the striatum, thalamus, dorsal anterior cingulate cortex (dACC), and prefrontal cortex (PFC). In line with our hypotheses, we found that methylphenidate decreased measures of connectivity and centrality in the striatum and thalamus in children with ADHD, but increased the same metrics in adults with ADHD. Surprisingly, we found no major effects of methylphenidate in the dACC and PFC in either children or adults. Interestingly, pre-methylphenidate, participants with ADHD showed aberrant connectivity and centrality compared to controls predominantly in frontal regions. Our findings demonstrate that methylphenidate's effects on connectivity of subcortical regions are age-dependent in stimulant-treatment naïve participants with ADHD, likely due to ongoing maturation of dopamine and noradrenaline systems. These findings highlight the importance for future studies to take a developmental perspective when studying the effects of methylphenidate treatment.

Keywords
ADHD, connectivity, graph-theory, methylphenidate, resting-state fMRI
INTRODUCTION

In recent years, attention-deficit/hyperactivity disorder (ADHD) has been increasingly considered a disorder of brain-wide network dysconnectivity rather than of region-specific deficits (Castellanos & Proal, 2012; Samea et al., 2019). Methylphenidate, the primary pharmacological treatment for ADHD, has been proposed to alter functional connectivity in various brain-wide functional circuits affected by ADHD (Pereira-Sanchez et al., 2020). For instance, normalized connectivity in fronto-parietal-cerebellar circuits has been observed in children with ADHD following acute methylphenidate. This was first observed by An et al., demonstrating that a single dose of methylphenidate compared to placebo, upregulated abnormally decreased local connectivity in bilateral ventral prefrontal cortices and the cerebellar vermis, and downregulated abnormally increased local connectivity in the right parietal and visual areas in children with ADHD (An et al., 2013). Similarly, Silk et al. found that a single dose of methylphenidate compared to placebo normalized increased functional connectivity in occipital, temporal, and cerebellar regions and visual, executive, and default mode networks in adolescents with ADHD (Silk et al., 2017). More recently, alterations in fronto-parietal-cerebellar circuits have also been observed following prolonged methylphenidate treatment in medication-naive children with ADHD (Yoo et al., 2018). Finally, preliminary evidence suggests that such a normalization might also occur in adults with ADHD (Cary et al., 2017; Picon et al., 2020). However, due to methodological heterogeneity in previous studies, including prior use of stimulant medications, results remain inconclusive (Pereira-Sanchez et al., 2020).

Methylphenidate acts by inhibiting dopamine and noradrenaline reuptake in the brain (Cortese et al., 2017). As the dopamine system undergoes significant alterations throughout development (Chen et al., 2010), methylphenidate-induced effects on functional connectivity may be modulated by age. For example, a recent longitudinal study demonstrated an age-dependent effect of prolonged stimulant treatment-response on cingulo-opercular network connectivity (Norman et al., 2019). Treatment-response on cingulo-opercular network connectivity may be modulated by age. For example, a recent longitudinal study demonstrated an age-dependent effect of prolonged stimulant treatment-response on cingulo-opercular network connectivity (Norman et al., 2019). Treatment-response on cingulo-opercular network connectivity may be modulated by age. For example, a recent longitudinal study demonstrated an age-dependent effect of prolonged stimulant treatment-response on cingulo-opercular network connectivity (Norman et al., 2019). Treatment-response on cingulo-opercular network connectivity may be modulated by age. For example, a recent longitudinal study demonstrated an age-dependent effect of prolonged stimulant treatment-response on cingulo-opercular network connectivity (Norman et al., 2019). Treatment-response on cingulo-opercular network connectivity may be modulated by age. For example, a recent longitudinal study demonstrated an age-dependent effect of prolonged stimulant treatment-response on cingulo-opercular network connectivity (Norman et al., 2019).

MATERIALS AND METHODS

We included 50 stimulant treatment-naive boys (10–12 years of age) and 49 stimulant-treatment-naive men (23–40 years of age) that were part of the “effects of Psychotropic drugs On the Developing brain - methylphenidate” (ePOD-MPH) trial (NTR3103 and NL34509.000.10; (Bottelier et al., 2014; Schrantee et al., 2016)). They were recruited through clinical programs at the Child and Adolescent Psychiatry Center Triversum (Alkmaar, The Netherlands), the Department of Child and Adolescent Psychiatry at the Bascule/AMC (Amsterdam, The Netherlands), and the PsyQ Mental Health Facility (The Hague, The Netherlands). All participants were diagnosed with ADHD (DSM-IV, all subtypes) by an experienced psychiatrist, using a structured interview, (Diagnostic Interview Schedule for Children (NIMH-DISC-IV): authorized Dutch translation (Ferdinand & van der Ende, 1998)) and the Diagnostic Interview for ADHD (DIVA 2.0) for adults (Kooij et al., 2008). In addition, as a typically developing comparison group, we included 11 boys (aged 10–12 years) and 12 men (aged 23–40 years) as non-ADHD control participants, who received pre-methylphenidate scans only (Table 1).

Exclusion criteria were: comorbid axis I psychiatric disorders requiring treatment with medication at study entry, a history of major neurological or medical illness or clinical treatment with drugs influencing the dopamine system (for adults before 23 years of age), such as stimulants, neuroleptics, antipsychotics, and/or D2/3 agonists (see Supplementary Material for more detail). The study was approved by the medical ethical committee and consequently monitored by the Clinical Research Unit of the Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. All participants and parents or legal representatives of the children provided written informed consent.

The primary outcome measure of the ePOD-MPH trial was to report on the modification by age of methylphenidate treatment on the outgrowth of the dopamine system by using pharmacologic MRI (Schrantee et al., 2016). Here, we report on acute effects of methylphenidate on the baseline rs-fMRI measurement of the trial, during which ADHD participants underwent two MRI scans, one before and one 90 min after an oral challenge of short-acting methylphenidate (Sandoz B.V., Weesp, the Netherlands; 0.5 mg/kg with a maximum of...
TABLE 1 Characteristics of participants included in the rs-fMRI analysis. Significant effects are indicated in bold (p < 0.05)

|                  | Children ADHD       | Controls ADHD | Adults ADHD       | Controls ADHD |
|------------------|----------------------|---------------|-------------------|---------------|
|                  | n = 33               | n = 10        | n = 48            | n = 11        |
|                  | mean ± SD            | mean ± SD     | mean ± SD         | mean ± SD     |
| Age (y)          | 11.4 ± 0.9           | 11.5 ± 0.8    | 28.5 ± 4.6        | 25.1 ± 1.9    |
| Estimated IQa    | 106.1 ± 18.9         | 101.8 ± 7.9   | 107.8 ± 7.5       | 108.0 ± 5.8   |
| ADHD subtype, no.|                      |               |                   |               |
| Inattentive      | 16                   | 16            |                   | -             |
| Hyperactive/impulsive | 1                | 0             | 33                | -             |
| Combined         | 16                   | -             | -                 | -             |
| ADHD symptoms    |                      |               |                   |               |
| DBD-RS Inattentionb | 21.7 ± 3.5          | 3.8 ± 3.0     |                   | -             |
| DBD-RS Hyperactivityb | 15.9 ± 5.5          | 4.0 ± 2.6     |                   | -             |
| ADHD-SRa         | -                    | -             | 32.7 ± 9.7        | 11.5 ± 5.6    |
| Depressive symptomsd | CDI 7.9 ± 4.2       | 3 ± 3.2       |                   | -             |
| Anxiety symptomsd | SCARED 26.4 ± 16.3   | 11.1 ± 6.6    |                   | -             |
| Framewise Displacement |                |               |                   |               |
| pre-MPH          | 0.04 ± 0.02          | 0.03 ± 0.008  | F(157) = 7.53, p < 0.01 | 0.01 ± 0.01  |
| post-MPH         | 0.03 ± 0.01          | -             | F(152) = 0.05, p = 0.83 | 0.01 ± 0.005 |
| MPH challenge, mg| 18.7 ± 2.2           | -             | 38.3 ± 2.6        | -             |

afor children: Wechsler Intelligence Scale for Children (WISC) (Kort et al., 2002); for adults: National Adults Reading Test (NART) (Schmand et al., 1992).
bDBD-RS = disruptive behavior disorder rating scale (Pelham Jr. et al., 1992).
cADHD-SR, Attention Deficit Hyperactivity Disorder-Self Report (Kooij, 2012).
dDepressive symptoms and anxiety symptoms: children: Child Depression Inventory (CDI) (Kovacs, 1985); Screen for Child Anxiety Related Disorders (SCARED) (Muris et al., 1998); adults: Beck’s Depression Inventory (BDI) (Beck et al., 1961); Beck’s Anxiety Inventory (BAI) (Beck et al., 1988).

20 mg in children and 40 mg in adults). The dose was chosen so that 80% of dopamine transporters were occupied (Swanson & Volkow, 2003), and we chose 90 min of waiting period for optimal occupation of these transporters. Typically developing control subjects did not receive a challenge of methylphenidate.

2.1 | Resting-state fMRI

Data were acquired on 3 T Philips scanners (Philips Healthcare, Best, The Netherlands) using an 8-channel receive-only head coil. A 3D T1-weighted anatomical scan was acquired for registration purposes, and resting-state fMRI (rs-fMRI) data were acquired using a single-shot echo-planar imaging sequence (TR/TE = 2300/30 ms, resolution = 2.3 × 2.3 × 3 mm, 39 sequential slices, FA = 80°, dynamics = 130).

Preprocessing was performed using FMRIIPREP v1.2.3 (Esteban et al., 2020; RRID:SCR_016216), including ICA-AROMA. Subsequently, white matter (WM) and cerebral spinal fluid (CSF) signals (obtained before ICA-AROMA) were regressed out and high-pass-filtering (100 s) was applied using FSL. The Brainnetome atlas was used to define 246 parcels ([Fan et al., 2016]; Figure 1a,b) and fMRI signal time-series per participant were extracted and z-scored (Figure 1c). Framewise displacement (FD) values were calculated from low-pass filtered motion parameter time-series according to Gratton et al. (2020) to remove respiration artifacts (Supplementary Methods) and fMRI signal timepoints where FD >0.2 mm were scrubbed. Participants were excluded from further analyses if mean FD >0.2 mm or if the number of volumes after scrubbing ≤104. Cleaned fMRI time-series were then used to calculate connectivity matrices using Pearson correlations, resulting in a 246 × 246 connectivity matrix per participant, which was absolutized for further analyses (Figure 1c,d). Temporal signal-to-noise ratio (tSNR) maps were calculated per participant to remove low-tSNR nodes (Supplementary Methods). Graph theory measures were calculated for the whole brain from connectivity matrices using the Brain Connectivity Toolbox ([Rubinov & Sporns, 2010]; [RRID:SCR_004841]; Figure 1e). Quality control measures as defined by Ciric et al. (2017), as well as the number of negative correlations and average correlation coefficients, were calculated (Supplementary Figure 1; Supplementary Table 1). Connectivity strength (CS), betweenness centrality (BC), and eigenvector centrality (EC) were calculated and consequently averaged for four regions of interest (ROIs): striatum, thalamus, dorsal anterior cingulate cortex (dACC), and prefrontal cortex (PFC) (Brainnetome region...
The striatum was selected because it is rich in dopamine transporters and is the primary target of methylphenidate. The thalamus and dACC were selected because animal literature has demonstrated the largest age-dependent effects of methylphenidate in these two important projections from the striatum (Andersen, 2005). Finally, the PFC was selected due to its hypothesized importance and its interconnection with other areas that are affected by ADHD (Mehta et al., 2019). We decided not to take lateralization into account, mainly for statistical reasons. An additional division into left and right would have significantly decreased the statistical power of our study. Additionally, we did not have any a-priori hypotheses about lateralization of methylphenidate induced resting-state connectivity changes in either the striatum, thalamus, dACC or the PFC, as pre-registered with the ePOD-MPH randomized controlled trial. Correlations of all connectivity measures and FD can be found in Supplementary Table 3. Further details on the analysis methods can be found in the Supplementary Material.

2.2 | Statistical analysis

Statistical analyses were conducted using R v.3.5.3 (R Development Core Team, 2011). All data were checked for normality and, in case of non-normality, log-transformed. Linear mixed-effects models were used to analyze changes in fMRI connectivity per age group separately to investigate the main effect of methylphenidate (pre- and post-challenge of acute methylphenidate) using the lme4 package (Bates et al., 2015). Linear models were used to analyze the differences between the ADHD participants and controls at pre-methylphenidate. The average whole-brain CS per participant was added to the model as a covariate. FD and a variable representing the scanner that was used were tested as possible covariates, but not significant and thus not included in the models. Multiple comparison correction within modalities was performed using Sidak’s correction: $\alpha^* = 1-(1-\alpha)^{1/m}$, with $\alpha = 0.05$ and $m = 4$ (number of ROIs), which resulted in an $\alpha^* = 0.0127$.

3 | RESULTS

3.1 | Participants

Of the 99 ADHD patients scanned, data from 81 participants with ADHD and 21 typically developing controls were analyzed (Table 1). One adult ADHD participant was excluded because of undisclosed prior stimulant treatment (more details about the trial
| Region of Interest | ADHD pre- vs. post-methylphenidate | ADHD (pre-methylphenidate) vs. controls | ADHD (post-methylphenidate) vs. controls |
|-------------------|-----------------------------------|----------------------------------------|----------------------------------------|
| **Striatum**      | Estimated mean difference [95% CIs]| Statistics                              | Estimated mean difference [95% CIs]    | Statistics                              | Estimated mean difference [95% CIs] | Statistics                              |
| **Children**      | Strength –9.3 [–9.6 –9.1]         | F(147) = 11.5, p < 0.01                | –0.7 [–5.4 4.07]                       | F(140) = 10.0, p = 0.03                 | 8.7 [4.2 13.2]                        | F(151) = 3.7, p = 0.06                  |
|                   | EC (×10^10) –0.8 [–0.8 –0.8]       | F(147) = 6.8, p = 0.01                | 0.07 [–0.3 0.5]                        | F(140) = 0.1, p = 0.97                 | 0.8 [0.5 1.3]                         | F(151) = 0.3, p = 0.03                  |
|                   | BC –16.4 [–16.8 –16.0]            | F(147) = 5.5, p = 0.02                | –10.5 [–23.5 2.6]                     | F(140) = 0.2, p = 0.64                 | 5.9 [–6.7 18.5]                       | F(151) = 0.1, p = 0.93                  |
| **Adults**        | Strength 8.2 [8.1 8.3]            | F(145) = 9.0, p < 0.01                | –6.6 [–10.5 –2.7]                     | F(152) = 1.8, p = 0.19                 | 14.8 [–18.8 –10.8]                    | F(154) = 11.1, p < 0.01                |
|                   | EC (×10^10) 0.9 [0.8 0.9]          | F(144) = 12.8, p < 0.01               | –0.5 [–0.9 –0.2]                      | F(152) = 1.3, p = 0.25                 | –1.4 [–1.6 –1.0]                      | F(154) = 0.7, p < 0.01                  |
|                   | BC 128 [12.5 13.0]               | F(145) = 1.4, p = 0.24                | 0.8 [–10.0 11.6]                      | F(152) = 0.1, p = 0.78                 | –12.0 [–23.0 –0.9]                    | F(154) = 0.9, p = 0.36                  |
| **Thalamus**      | Strength –13.8 [–14.0 –13.6]      | F(147) = 37.9, p < 0.01               | –2.9 [–7.1 1.4]                       | F(140) = 4.6, p = 0.04                 | 10.9 [6.9 14.97]                      | F(151) = 8.6, p < 0.01                 |
|                   | EC (×10^10) –1.2 [–1.3 –1.2]       | F(146) = 32.3, p < 0.01               | –0.2 [–0.6 0.1]                       | F(140) = 2.0, p = 0.17                 | 0.9 [0.6 1.4]                         | F(151) = 0.6, p = 0.03                  |
|                   | BC –20.9 [–21.2 –20.5]            | F(147) = 13.8, p < 0.01               | –10.6 [–1.4 19.8]                     | F(140) = 0.1, p = 0.83                 | 10.3 [1.5 19.1]                       | F(151) = 0.1, p = 0.93                  |
| **Adults**        | Strength 9.4 [9.3 9.5]            | F(145) = 12.4, p < 0.01               | –3.1 [–6.6 0.4]                       | F(152) = 0.7, p = 0.41                 | –12.5 [–16.1 –9.0]                    | F(154) = 7.6, p < 0.01                 |
|                   | EC (×10^10) 0.9 [0.9 0.9]          | F(145) = 13.5, p < 0.01               | –0.2 [–0.6 0.1]                       | F(152) = 0.5, p = 0.50                 | –1.2 [–1.5 –0.9]                      | F(154) = 0.7, p < 0.01                  |
|                   | BC 131 [13.0 13.3]              | F(144) = 8.0, p = 0.01                | 20.7 [12.3 29.1]                      | F(152) = 10.7, p < 0.01               | 7.6 [–0.9 16.2]                       | F(154) = 4.3, p = 0.04                  |
| **dACC**          | Strength 4.6 [4.4 4.8]            | F(147) = 5.6, p = 0.02                | –3.2 [–7.0 0.72]                      | F(140) = 3.1, p = 0.08                 | –7.7 [–11.4 –4.0]                     | F(151) = 4.4, p = 0.04                  |
|                   | EC (×10^10) 0.4 [0.4 0.4]          | F(147) = 4.4, p = 0.04                | 0.1 [–0.2 0.5]                        | F(140) = 0.1, p = 0.90                 | –0.3 [–0.7 0.1]                       | F(151) = 0.2, p = 0.68                  |
|                   | BC 61.9 [60.0 63.8]              | F(146) = 5.7, p = 0.02                | 67.4 [30.2 103.6]                     | F(140) = 2.6, p = 0.11                 | 5.5 [–29.8 40.8]                      | F(151) = 0.1, p = 0.96                  |
| **Adults**        | Strength 1.6 [1.5 1.7]            | F(145) = 0.4, p = 0.55                | –12.9 [–16.1 –9.7]                    | F(152) = 8.3, p < 0.01                 | –14.5 [–11.2 17.8]                    | F(154) = 13.7, p < 0.01                |
|                   | EC (×10^10) 0.1 [0.0 0.1]          | F(145) = 0.7, p = 0.41                | –1.1 [–1.4 –0.7]                      | F(152) = 7.3, p < 0.01                 | –1.2 [–1.5 –0.8]                      | F(154) = 11.4, p < 0.01                |
|                   | BC –9.6 [–10.6 –8.6]            | F(145) = 0.9, p = 0.36                | 50.6 [17.0 84.3]                      | F(152) = 3.1, p = 0.08                 | 60.2 [25.6 94.9]                      | F(152) = 6.4, p = 0.01                  |
| **PFC**           | Strength –6.6 [–6.9 –6.2]         | F(146) = 2.0, p = 0.16                | 15.7 [8.0 23.3]                       | F(140) = 9.2, p < 0.01                 | 22.2 [14.9 29.5]                      | F(151) = 16.7, p < 0.01                |
|                   | EC (×10^10) –0.1 [–0.1 –0.1]       | F(145) = 0.1, p = 0.83                | 0.03 [–0.2 0.3]                       | F(140) = 1.2, p = 0.27                 | 0.1 [–0.1 0.3]                        | F(151) = 0.7, p = 0.40                  |
|                   | BC 135 [12.7 14.2]              | F(146) = 3.2, p = 0.08                | –15.3 [–30.4 –0.14]                  | F(140) = 5.7, p = 0.02                 | –28.8 [–43.3 –14.4]                   | F(151) = 8.9, p < 0.01                  |
are published elsewhere (Schrantee et al., 2016). Seventeen children with ADHD were excluded due to excessive motion (whose characteristics did not differ from the included children (Supplementary Results)).

3.2 | Rs-fMRI connectivity

All results of the statistical tests, as well as the estimated means and 95% confidence intervals, can be found in Table 2.

3.2.1 | Striatum

Pre- to post-methylphenidate, in children with ADHD, CS, and EC significantly decreased, but changes in BC did not survive multiple comparison corrections. Pre- to post-methylphenidate, in adults with ADHD, the opposite effect was found; both CS and EC significantly increased, but BC did not change significantly.

Pre-methylphenidate, neither children nor adults with ADHD differed significantly from the respective controls in any of the connectivity metrics. Post-methylphenidate, in children with ADHD, none of the connectivity metrics differed significantly from the respective young controls. Post-methylphenidate, in adults with ADHD, CS and EC differed significantly from the adult controls, but BC did not differ significantly. (Figure 2a; Table 2).

3.2.2 | Thalamus

Pre- to post-methylphenidate, in children with ADHD, CS, EC, and BC decreased significantly. Pre- to post-methylphenidate, in adults with ADHD, the opposite effect was found; CS, EC, and BC increase significantly. Pre-methylphenidate, children with ADHD did not differ significantly from the young controls in any of the connectivity metrics.

Pre-methylphenidate, adult ADHD participants showed lower BC than adult controls, but CS and EC did not differ significantly. Post-methylphenidate, in children with ADHD, CS was significantly different from the respective controls, but EC and BC were not significantly different. Post-methylphenidate, in adults with ADHD, CS and EC were significantly different from the respective controls (Figure 2b; Table 2).

3.2.3 | dACC

Pre- to post-methylphenidate, in children with ADHD, CS, BC and EC changes did not survive multiple comparison corrections. Pre- to post-methylphenidate, in adults with ADHD, none of the connectivity metrics changed significantly.
Pre-methylphenidate, children with ADHD did not differ significantly from the respective controls in any of the connectivity metrics. Pre-methylphenidate, adult ADHD participants showed higher CS and EC values than the adult controls, but BC did not differ significantly. Post-methylphenidate, in children with ADHD, none of the connectivity metrics differed from the controls. Post-methylphenidate, in adults with ADHD, CS and EC did not survive multiple comparison corrections, BC was found to increase significantly.

Pre-methylphenidate, children with ADHD showed significantly higher CS values than controls. None of the other connectivity measures differed significantly. Adults with ADHD showed no differences to controls in CS, but significantly higher EC values and lower BC values than the control group. Post-methylphenidate, in children with ADHD, EC was not significantly different from the young controls, but CS and BC were found to be significantly different. Post-methylphenidate, in adults with ADHD, none of the connectivity metrics were significantly different from the adult controls (Figure 2d; Table 2).

### 3.2.4 | PFC

Pre- to post-methylphenidate, in children with ADHD, none of the graph-theory metrics changed significantly. Pre- to post-methylphenidate, in adults with ADHD, CS and EC did not survive multiple comparison corrections, BC was found to increase significantly.

Pre-methylphenidate, children with ADHD showed significantly higher CS values than controls. None of the other connectivity measures differed significantly. Adults with ADHD showed no differences to controls in CS, but significantly higher EC values and lower BC values than the control group. Post-methylphenidate, in children with ADHD, EC was not significantly different from the young controls, but CS and BC were found to be significantly different. Post-methylphenidate, in adults with ADHD, none of the connectivity metrics were significantly different from the adult controls (Figure 2d; Table 2).
4 | DISCUSSION

The goal of this study was to investigate the effects of acute methylphenidate on rs-fMRI connectivity in stimulant-treatment naïve children and adults with ADHD. In line with our hypotheses, we found that methylphenidate decreased measures of connectivity and centrality in subcortical ROIs in children with ADHD, but increased the same metrics in adults with ADHD, indicating an age-dependent acute effect of methylphenidate in dopamine-sensitive regions. Surprisingly, we found no major effects of methylphenidate in frontal ROIs in either children or adults. Interestingly, at pre-methylphenidate, participants with ADHD showed aberrant connectivity and centrality predominantly in frontal ROIs compared to controls.

4.1 | Effect of methylphenidate in children with ADHD

A recent review on the effects of stimulant medication on rs-fMRI connectivity in individuals with ADHD shows that methylphenidate appears to modulate several rs-fMRI networks, but the number of studies is small, and the results are heterogeneous (Pereira-Sanchez et al., 2020). In line with findings from Silk et al. (2017), we observed that acute methylphenidate decreased connectivity in the striatum and thalamus, whereas in the dACC we found nonsignificant increases in connectivity after a single dose of methylphenidate. This is in agreement with a previous study reporting that acute methylphenidate increased connectivity in frontal regions (An et al., 2013). Notwithstanding, our study has some methodological differences compared to previous studies. Firstly, all our participants were stimulant-treatment naïve, whereas in other studies medication status was inconsistent. Therefore, our study rules out the influence of prior medication on connectivity through prolonged effects of stimulants on the dopamine system. For example, prolonged MPH treatment has been shown to impact (proxy measures of) dopamine function in juvenile animals and children (Andersen, 2005; Moll et al., 2001; Schrantee et al., 2016). Furthermore, long-term stimulant treatment normalized delayed structural maturation of the PFC in individuals with ADHD, which may reflect dopaminergic adaptive processes (Castellanos et al., 2002; Shaw et al., 2009).

Secondly, we assessed graph theory metrics, whereas Silk et al., 2017 used Network Based Statistics to identify connections that are affected by methylphenidate, and An et al., 2013 used regional homogeneity, reflecting local synchronized brain activity, considered to be a measure of functional segregation (Lv et al., 2018). As such, our study extends prior literature from connectivity metrics to topology metrics, which allows us to not only assess individual nodes or global connectivity, but to assess the importance and integration of pre-specified nodes within the global network. In subcortical regions, methylphenidate affects average connectivity (CS) and nodal importance (EC), suggesting changes in the role of these regions in both local and global network topology. In frontal regions on the other hand, we observe marginal increases in global importance (BC) following methylphenidate, which might indicate a more important role for these regions regarding information flow in the network (Farahani et al., 2019; Wang et al., 2010). Thirdly, both previous studies included placebo conditions, whereas we used a pre-post design. Finally, the dose that we used was slightly higher than Silk et al. (2017: 0.41 mg/kg) and substantially higher than An et al. (10 mg), which may have affected functional connectivity differently (An et al., 2013), particularly considering the inverted-U relationship between dopamine levels and cognition (Arnsten & Rubia, 2012; Froudist-Walsh et al., 2020).

Although previous studies have reported that methylphenidate normalizes brain activity (Czerniak et al., 2013; Rubia, 2011) and connectivity (An et al., 2013), our results do not support these findings. Instead, in accordance with a recent meta-analysis (Cortese et al., 2021), pre-methylphenidate, we show no group differences in connectivity in subcortical ROIs, and our findings suggest that methylphenidate-induced changes in connectivity deviate from the control-like state. We could speculate that these discrepancies are due to divergent brain development in ADHD, affecting local vs. global metrics differently. As such, methylphenidate could normalize local connectivity and activity, as demonstrated by previous studies, but compensate for altered network structure on a global level, as found here. Alternatively, the deviation from the control-like state (“normal” to “abnormal”) may also represent potential “side effects” of the medication. Future studies are needed to determine whether these different connectivity patterns reflect compensatory processes or unwanted side effects of medication. In the PFC on the other hand, we found higher CS compared to controls, one of the latest brain regions to mature (Mills et al., 2014). This is partly in line with two recent meta-analyses proposing increased connectivity within the executive control network in children with ADHD (Gao et al., 2019; Sutcu et al., 2020), potentially reflecting greater mental effort to compensate for executive function in ADHD.

4.2 | Effect of methylphenidate in adults with ADHD

The present study is, to our knowledge, the first to investigate the acute effects of methylphenidate in stimulant-treatment naïve adults with ADHD. In agreement with our hypotheses, our findings indicate that methylphenidate increased overall connectivity and importance of striatal and thalamic nodes within the brain network. Our results show overlap with regions identified in a study investigating prolonged effects of methylphenidate in adults (Cary et al., 2017), and correspond to findings from typically-developing adults showing that acute methylphenidate increased connectivity between the thalamus and attention networks, and subcortical regions (Farr et al., 2014; Mueller et al., 2014). These findings, together with the absence of major differences in connectivity when compared to controls, suggest that the mechanisms underlying the effects of methylphenidate on subcortical connectivity are largely comparable between adults with and without ADHD. However, this is in contrast with evidence from
Positron Emission Tomography (PET) studies reporting significant differences in striatal dopamine release between adults with ADHD and controls following a stimulant challenge; albeit in different directions (Cherkasova et al., 2014; Volkow et al., 2007). Together, this suggests that differential effects of methylphenidate on subcortical dopamine release may not directly translate into differential subcortical connectivity between individuals with ADHD and controls. The pattern observed in cortical regions is more complex. In the dACC, methylphenidate did not induce changes in connectivity in participants with ADHD, despite higher pre-methylphenidate connectivity compared to controls. Such hyperconnectivity (Guo et al., 2020) could be speculated to be a result of developed compensatory processes, in response to reduced network efficiency (Konrad & Eickhoff, 2010), particularly in adults who were never treated with ADHD medication. Interestingly, the absence of normalized dACC after methylphenidate could suggest that such processes are dopamine and noradrenaline-independent. Alternatively, individual differences may be too large to observe group differences, or such processes affect other network measures than those studied here. Conversely, in the PFC, we found that BC increased, whereas CS and EC decreased after methylphenidate. This would mean that methylphenidate increases the role of the PFC as a global communication hub (i.e., BC), but reduces connectivity of the PFC with other regions (i.e., CS and EC); meaning that the PFC connections become more specialized for network communication.

### 4.3 Age-dependent effects of methylphenidate in ADHD

The effects of methylphenidate on the brain have been proposed to be age-dependent (Andersen, 2005; Canese et al., 2009; Norman et al., 2021b). Indeed, we previously showed that thalamic cerebral blood flow was reduced following acute methylphenidate in children, but not in adults with ADHD (Schrantee et al., 2016). Accordingly, we here find an opposite effect of acute methylphenidate in thalamic and striatal connectivity in children compared to adults. Nevertheless, these age-effects may not be specific to ADHD, as functional connectivity changes over development, complicating intergenerational comparisons (Tooley & Bassett, 2021; Vâsa et al., 2020). Functional segregation appears predominant in children, whereas functional integration prevails in adults. Systems neuroscience models, suggest that increased segregation reflects efficient network functioning, and that excessive integration can be a correlate of brain dysfunction. If excessive cross-network functional integration were confirmed to be a consistent feature of ADHD, it could represent a therapeutic target (Pereira-Sanchez et al., 2021; Wig, 2017). As such, typical development of functional connectivity is characterized by simultaneous reduction of local circuitry and strengthening of long-range connectivity (Grayson & Fair, 2017; Supek et al., 2010). Nevertheless, we can speculate that the difference in methylphenidate-induced connectivity changes between children and adults might result from maturation of dopaminergic and noradrenergic systems (Chen et al., 2010). For instance, adults display a more segregated architecture in the frontoparietal network, including the dorsal basal ganglia (i.e., caudate nucleus) (Fair et al., 2009), possibly through changes in the dopamine system in the frontal cortex (Rosenberg & Lewis, 1994; Lidow et al., 1991; Lidow & Rakic, 1992). This network is, for example, important for the top-down regulation of emotion and attention (Zhou et al., 2007). Indeed, a recent longitudinal study on the effects of stimulant treatment response and age found a significant influence on cingulo-opercular network connectivity (Norman et al., 2021b).

The age-dependent effects on striatal and thalamic connectivity reported here could therefore be due to compensatory mechanisms taking place in the adults, especially given that they were stimulant-treatment naïve before the study. It has been argued that the neuropathology of childhood remittent cases could be attributed largely to a delayed frontal cortex maturation, whereas the neuropathology of persistent cases is linked more to pathology in extra-frontal and subcortical structures (Francx et al., 2015). In summary, this suggests that the efficacy of stimulant therapy may not be based on normalization only, but rather depend on combinations of factors that return the network organization to typical topology for some systems while reorganizing others. In other words, it might be that altered networks in the brain do not need to return to the control state to function in the desired way, a restructuring of function could be sufficient. It is therefore important that future studies take age-dependent effects into account.

In addition, previous studies have suggested potential neural differences between persistent and remitted adults with ADHD (Mattfeld et al., 2014). By definition, our adult ADHD sample had persistent ADHD, whereas this remains to be assessed for our pediatric sample (Caye et al., 2016; Kessler et al., 2005). Longitudinal (f)MRI studies on ADHD persisters and remitters with childhood ADHD will be crucial to gain more insight into the differences in brain connectivity of persisting and remitting ADHD in childhood (Rubia, 2018). Speculatively, in addition to developmental differences, our results may partially be explained by neuronal differences between these two ADHD phenotypes. Norman et al., indeed found reduced connectivity within the inferior frontal gyrus in children with ADHD to be indicative of longitudinal risk for ADHD inattention symptoms (Norman et al., 2021a). Additionally, because we included stimulant-treatment naïve individuals with ADHD, the adults might not represent a typical sample, as most adults with ADHD will receive medication before adulthood. For a long time it has been debated if ADHD may also be developed in adulthood, with no previous symptoms in childhood (‘adult-onset ADHD’; Castellanos, 2015). However, a recent review argues that symptoms in adults indeed exist but that their source would be either symptoms that were previously surpassed, were not properly assessed before, or not detected earlier (Taylor et al., 2021).

One of the main strengths of this study is that we included both stimulant-treatment naïve boys and men with ADHD and that, compared to previous studies on the acute effects of methylphenidate, we included a larger number of participants. However, limitations of our study are that the results cannot be extrapolated to all children and
adults with ADHD, because we only studied participants with restricted age ranges. Furthermore, we included only male participants to reduce heterogeneity, but this limits the generalizability to female participants. Additional studies are needed in females, since female sex hormones modulate dopamine transporter expression (Wagner et al., 2007). Furthermore, the comparisons between participants with ADHD and control participants have to be interpreted with caution, due to the small control groups and because control participants did not receive a methylphenidate challenge. Ethical considerations did not permit us to administer methylphenidate to the young controls, therefore, the controls were assessed only once. Due to this limitation, we cannot fully exclude the possibility of a scan order effect causing differences, even though children and adults showed effects in opposite directions in this study, which makes that explanation unlikely. Moreover, we acquired only a relatively short scan of ~5 min, which might have made the intra-/intersession reliability lower.

5 | CONCLUSION

Taken together, in line with our hypothesis, we found opposing effects of acute methylphenidate on connectivity strength and the relative importance of the nodes in subcortical regions, in children compared to adults. In contrast with what we expected, MPH-induced changes in connectivity of frontal cortical regions were marginal. They did not indicate differences between age groups, and mainly global importance of these regions (i.e., their importance as a hub) within the network was increased. Therefore, we conclude that acute methylphenidate-effects on connectivity measures in dopamine-sensitive subcortical, but not cortical regions, are different in children and adults with ADHD, possibly due to changes of the dopamine and noradrenergic systems during maturation. These findings highlight the importance for future studies to investigate the age-dependent effects of long-term methylphenidate treatment, ideally in previously medication-naive individuals, on graph-theoretical connectivity measures, with a focus on centrality measures of subcortical regions. Additionally, we did not find normalizing effects of acute methylphenidate in either of the age groups, indicating that the previously found normalization towards a control state might be present on the local connectivity level, whereas on the global network level methylphenidate may give rise to reorganization of function.

AUTHOR CONTRIBUTION

All authors made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data, drafted the article or revised it critically for important intellectual content, and approved the version to be published.

ACKNOWLEDGEMENTS

We thank all participants and their parents for participating in this study and all students who helped collect and analyze the data.

CONFLICT OF INTEREST

This study was funded by a personal research grant awarded to LR by the Academic Medical Center, University of Amsterdam, and 11.32050.26 ERA-NET PRIOMEDCHILD FP 6 (EU) and a grant from Amsterdam Brain and Cognition (ABC). AK was supported by Suffixgium, a Dutch nonprofit organization, and Amsterdam Neuroscience. AK and LR were financially supported by EUROSTARS (E1113.351 DEPENDICT). AS is supported by the NWO (Veni: 016.196.153) and the Urban Mental Health program of the University of Amsterdam. The authors have nothing to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Antonia Kaiser https://orcid.org/0000-0001-7805-6766

REFERENCES

An, L., Cao, X. H., Cao, Q. J., Sun, L., Yang, L., Zou, Q. H., Katya, R., Zang, Y. F., & Wang, Y. F. (2013). Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder. Neuropsychopharmacology, 38, 1287–1295. Andersen, S. L. (2005). Stimulants and the developing brain. Trends in Pharmacological Sciences, 26, 237–243. Arnsten, A. F. T., & Rubia, K. (2012). Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: Disruptions in neurodevelopmental psychiatric disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 51, 356–367. Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015). Fitting linear mixed-effects models using lme4. Journal of Statistical Software, 67, 1–48. Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology, 56, 893–897. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561–571. Botteler, M. A., Schouw, M. L. J., Klomp, A., Tamminga, H. G. H., Schraantt, A. G. M., Bouziane, C., de Ruiter, M. B., Boer, F., Ruhé, H. G., Denys, D., Rijsman, R., Lindauer, R. J. L., Reitsma, H. B., Geurts, H. M., & Reneman, L. (2014). The effects of psychotropic drugs on developing brain (ePOD) study: Methods and design. BMC Psychiactry, 14, 14-48. Canese, R., Adriani, W., Marco, E. M., De Pasquale, F., Lorenzini, P., De Luca, N., Fabi, F., Podo, F., & Laviola, G. (2009). Peculiar response to methylphenidate in adolescent compared to adult rats: A phMRI study. Psychopharmacology, 203, 143–153. Cary, R. P., Ray, S., Grayson, D. S., Painter, J., Carpenter, S., Maron, L., Sporns, O., Stevens, A. A., Nigg, J. T., & Fair, D. A. (2017). Network structure among brain systems in adult ADHD is uniquely modified by stimulant administration. Cerebral Cortex, 27, 3970–3979. Castellanos, F. X. (2015). Is Adult-Onset ADHD a Distinct Entity? American Journal of Psychiatry, 172, 929–931. https://doi.org/101176/appi.ajp.201515070988. Castellanos, F. X., & Proal, E. (2012). Large-scale brain systems in ADHD: Beyond the prefrontal-striatal model. Trends in Cognitive Sciences, 16, 17–26. Castellanos, X. F., Patti, L. P., Sharp, W., Jeffries, N. O., Greenstein, D. K., Claesen, L. S., Blumenthal, J. D., James, R. S., Eben, C. L., Walter, J. M., Zijdenbos, A., Evans, A. C., Giedd, J. N., & Rapoport, J. L. (2002). Developmental trajectories of brain volume abnormalities in children and
adolescents with attention-deficit/hyperactivity disorder. *Journal of the American Medical Association*, 288, 1740–1748.

Caye, A., Spadini, A. V., Karam, R. G., Grevet, E. H., Rovaris, D. L., Bau, C. H. D., Rohde, L. A., & Kieling, C. (2016). Predictors of persistence of ADHD into adulthood: A systematic review of the literature and meta-analysis. *European Child & Adolescent Psychiatry*, 25(112), 1151–1159.

Chen, Y. I., Choi, J. K., Xu, H., Ren, J., Andersen, S. L., & Jenkins, B. G. (2010). Pharmacographic neuroimaging of the ontogeny of dopamine receptor function. *Developmental Neuroscience*, 32, 125–138.

Cherkasova, M. V., Faridi, N., Casey, K. F., O'Driscoll, G. A., Hechtman, L., Joober, R., Baker, G. B., Palmer, J., Dagher, A., & Leyton, M. (2014). Benkelfat C (2013): Amphetamine-induced dopamine release and neuropsychometric function in treatment-naïve adults with ADHD. *Neuropsychopharmacology*, 39(39), 1499–1507.

Cortese, S., Aoki, Y. Y., Itahashi, T., Castellanos, F. X., & Eickhoff, S. B. (2021). Systematic review and meta-analysis: Resting-state functional magnetic resonance imaging studies of attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*, 60, 61–75.

Cortese, S., D'Acunto, G., Konofal, E., Masi, G., & Vitiello, B. (2017). New formulations of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Pharmacokinetics, efficacy, and tolerability. *CNS Drugs*, 31, 149–160.

Czemlaš, S. M., Sikoglu, E. M., King, J. A., Kennedy, D. N., Mick, E., Frazer, J., & Moore, C. M. (2013). Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: A systematic review. *Harvard Review of Psychiatry*, 21, 151–162.

Rosenberg, D. R., & Lewis, D. A. (1994). Changes in the dopaminergic innervation of monkey prefrontal cortex during late postnatal development: A tyrosine hydroxylase immunohistochemical study. *Biological Psychiatry*, 36, 272–277.

Esteban, O., Ciric, R., Finc, K., Blair, R. W., Markiewicz, C. J., Moodie, C. A., Kent, J. D., Goncalves, M., DuPre, E., Gomez, D. E., Ye, Z., Salo, T., Valabrega, R., Amlens, I. K., Lien, F., Jacoby, N., Stojić, H., Cieslak, M., Urch, S., Gorgolewski, K. J. (2020). Analysis of task-based functional MRI data preprocessed with FMRIPrep. *Nature Protocols*, 15, 1–17.

Fair, D. A., Cohen, A. L., Power, J. D., Dosenbach, N. U. F., Church, J. A., Zheng, Z., Miezin, F. M., Schlaggar, B. L., & Petersen, S. E. (2009). Functional connectivity of the default network is reduced in adults with ADHD. *NeuroImage*, 47, 856–868.

Kooij, S. J. J., Boonstra, A. M., Swinkels, S. H. N., Bekker, E. M., de Noord, I., Buitelaar, J. K., Sandra, Kooij, J. J., Marije Boonstra, A., Swinkels, S. H. N., Bekker, E. M., de Noord, I., & Buitelaar, J. K. (2008). Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. *Journal of Attention Disorders*, 11, 445–458.

Kort W, Compaan E, Bleichrodt R, N, Resing WCM, Schittekatte M, Bosmans M (2002): WISC-iii NL. London Psychol Corp.

Kovacs, M. (1985). The Children's depression inventory (CDI). *Psychopharmacology Bulletin*, 21, 955–998.

Lv, H., Wang, Z., Tong, E., Williams, L. M., Zaharchuk, G., Zeineh, M., Goldstein-Piekarski, A. N., Ball, T. M., Liao, C., & Wintermark, M. (2018). Resting-state functional MRI: Everything that nonexperts have always wanted to know. *American Journal of Neuroradiology*, 39, 1390–1399.

Mattfeld, A. T., Gabrieli, J. D. E., Biederman, J., Spencer, T., Brown, A., Kotte, A., Kagan, E., & Whitfield-Gabrieli, S. (2014). Brain differences wanted to know. *American Journal of Psychiatry*, 271, 1390–1399.

Mehta TR, Monergo A, Nene Y, Fayyaz M, Bollu PC (2019): Neurobiology of ADHD: A review. Current Developmental Disorders Reports. Springer.

Mills, K. L., Goddings, A. L., Clasen, L. S., Giedd, J. N., & Blakemoore, S. J. (2014). The developmental mismatch in structural brain maturation during adolescence. *Developmental Neuroscience*, 36, 147–160.

Moll, G. H., Hause, S., Rüther, E., Rothenberger, A., Huetter, G., & Al, M. E. T. (2001). Early methylphenidate administration to young rats. *Journal of Child and Adolescent Psychopharmacology*, 11, 15–24.

Lidow, M. S., Tozzi CP, Huchison R, N, Scherer M, Keeser D, Pogarell O, Berman A, Coates U, Reiser M, Fiedel, M, Möller H, J, Ettlinger U, & Meinl, T. (2014). The effects of methylphenidate on whole brain intrinsic functional connectivity. *Human Brain Mapping*, 35, 5379–5388.
